The Gut-Brain Axis Goes Clinical

By Dr. Ruseik Rahumath · 23 June 2026 · 6 min read

My maternal grandfather was a "wedha mahaththaya" — a traditional physician in rural Sri Lanka who specialized in treating snake and animal bites. He died before I was born. I never met him.

Years ago, while going through some old family papers, I found his notes. Among the herbal formulations and treatment protocols, one entry stopped me cold: he had classified 12 distinct types of rats.

Twelve. I laughed at first. I grew up in the same area. We barely have three or four recognizable rodent species in the surrounding environment. What was he documenting?

Then I read closer. The descriptions weren't about rodent taxonomy. They were about what happened to people after rat bites — the fever pattern, the wound characteristics, the progression of symptoms, the time to deterioration. He had built a syndromic classification system. Cellulitis, systemic infection, wound abscess, even tetanus-like picture — we now study these as distinct clinical entities under different areas. He was mapping through his own method and observation across decades of practice. Pattern recognition without a microscope. Epidemiology before we had the word.

I've been thinking about this a lot recently, as I've been diving into a very different body of evidence: the gut-brain axis and its emerging role in mental health.

The Evidence: From Hypothesis to Clinical Trial

For years, the idea that gut bacteria could influence mood felt like a fascinating but speculative hypothesis. That's changed. The question is no longer whether the microbiome affects the brain — it's how precisely, through which mechanisms, and for which patients.

A 2024 systematic review by Mosquera and colleagues examined 51 randomized clinical trials involving 3,353 patients, testing psychobiotics (probiotic strains selected for their capacity to influence mental health) in adults with psychiatric and cognitive disorders. Their analysis found notably high effectiveness specifically for depression symptoms. Most trials used strains of Lactobacillus and Bifidobacterium over treatment periods of 4 to 24 weeks.[1]

At the individual trial level, Tian et al. (2022) conducted a particularly rigorous study: a randomized, double-blinded, placebo-controlled trial of Bifidobacterium breve CCFM1025 in 45 patients with major depressive disorder. Over four weeks, the treatment group showed significantly greater improvement on both the Hamilton Depression Rating Scale and the Montgomery-Åsberg Depression Scale, with effect sizes in the moderate range (Cohen's d ≈ 0.64). More importantly, the investigators didn't just measure symptoms. They measured serum serotonin turnover, gut microbiome composition, and tryptophan metabolites. CCFM1025 significantly reduced serotonin turnover compared with placebo, suggesting the strain directly influences serotonergic signaling through tryptophan metabolism.[2]

In a different population, Sarkawi et al. (2024) tested a dual-strain Lactobacillus cultured milk drink in 110 irritable bowel syndrome patients with subthreshold depression. After 12 weeks, the probiotic group showed significant reductions in depression scores and a significant rise in serum serotonin levels compared with baseline. The placebo group also improved on depression scores (a reminder that gastrointestinal symptom relief itself can lift mood) but only the probiotic group showed the neurochemical change in serotonin.[3]

FMT: Transferring Depression Through the Microbiome

Perhaps the most striking evidence comes from the fecal microbiota transplantation (FMT) domain. Liu P. and colleagues (2024) characterized the gut microbiota of patients with inflammatory depression (a treatment-resistant subtype marked by elevated inflammatory markers) and then performed FMT from these patients to antibiotic-depleted mice. The recipient mice developed depressive and anxiety-like behaviors, along with increased peripheral and central inflammatory factors and intestinal mucosal permeability. The behavioral phenotype was transferred via microbiota alone. Conversely, administration of Clostridium butyricum (a butyrate-producing bacterial species) normalized the gut microbiota, decreased inflammatory factors, and produced antidepressant-like effects in the mouse model.[4]

This is hinting at causal evidence, not just correlation. You can take the gut bacteria from a depressed human, put them into a mouse, and the mouse becomes depressed. Then you can reverse it with a single bacterial species that produces butyrate.

How Microbes Talk to the Brain

Three primary mechanisms recur across the literature, and they're not mutually exclusive.

First, tryptophan metabolism: gut bacteria compete for tryptophan, the precursor to serotonin, and influence whether it gets diverted down the kynurenine pathway — which under inflammatory conditions produces neurotoxic metabolites.[5]

Second, short-chain fatty acids: bacterial fermentation of dietary fiber produces butyrate, which strengthens intestinal tight junctions, reducing bacterial translocation and systemic endotoxemia.[5]

Third, immune modulation: dysbiosis can increase intestinal permeability, allowing bacterial lipopolysaccharide to enter circulation and trigger neuroinflammation through microglial activation.[6]

The Limits of What We Know

I need to be clear about what this evidence doesn't mean. Psychobiotics are not ready to replace antidepressants as first-line therapy. The largest individual RCTs enroll fewer than 120 participants. No trial has followed patients beyond 24 weeks — we have no idea whether benefits persist after stopping probiotics. Strain specificity is poorly understood: two strains of the same species can have dramatically different functional properties. Publication bias is likely — positive trials are more likely to be published. And dietary confounds are almost never controlled: what a patient eats during a probiotic trial could independently shape the microbiome and amplify or mask the treatment effect.

We're on page one of this book. Nobody should be making clinical claims beyond what the evidence supports.

What I Tell Patients

At the bedside, with a patient who's struggling with depression, especially if they have gastrointestinal symptoms or partial response to medication, I don't always prescribe something new. Sometimes I just tell them: "There's emerging evidence that the bacteria in your gut communicate with your brain. Scientists are testing specific probiotic strains for depression. The research is early but real. Here's what we know."

That conversation does something. It validates their experience without pathologizing it further. It opens a door they didn't know existed. It gives them a mental model for their own health that includes their body, not just their brain chemistry.

The Weda Mahaththaya's Lesson

Which brings me back to my grandfather's 12 types of rats. He didn't have a microscope. He didn't know about Streptobacillus moniliformis or anaerobic culture techniques. But across decades of careful observation, he built a classification system that mapped onto reality. The pattern was there. The mechanism came later, if at all.

I'm not romanticizing tradition. The same rigorous standard of evidence should apply to all knowledge systems before they pass my clinical judgment. Fermented foods are not automatically medicine because they're ancestral. But the instinct to dismiss pre-scientific medical systems as pure superstition — that instinct is also a bias. Some of what our ancestors maintained through practice and observation may carry secrets we're only beginning to decode through the lens of microbiome science, metabolomics, and neuroimmunology.

Open mind. Equal rigor. No shortcuts. That's where I stand.

References

  1. Mosquera FEC et al. Effectiveness of Psychobiotics in Psychiatric and Cognitive Disorders. Nutrients. 2024. PMID 38732599.
  2. Tian P et al. B. breve CCFM1025 attenuates MDD via gut microbiome and tryptophan metabolism. Brain Behav Immun. 2022. PMID 34875345.
  3. Sarkawi M et al. Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in IBS. Sci Rep. 2024. PMID 38658619.
  4. Liu P et al. Immunoregulatory role of gut microbiota in inflammatory depression. Nat Commun. 2024. PMID 38589368.
  5. Liu L et al. Gut microbiota and its metabolites in depression. EBioMedicine. 2023. PMID 36963238.
  6. Clerici L et al. Gut Microbiome, Diet and Depression. Curr Nutr Rep. 2025. PMID 39928205.